Available online on 15.05.2026 at http://jddtonline.info

Journal of Drug Delivery and Therapeutics

Open Access to Pharmaceutical and Medical Research

Copyright  © 2026 The   Author(s): This is an open-access article distributed under the terms of the CC BY-NC 4.0 which permits unrestricted use, distribution, and reproduction in any medium for non-commercial use provided the original author and source are credited

Open Access Full Text Article   Review Article

Global Trends and Burden of Diabetes Mellitus (DM): A Comprehensive Review of Epidemiology, Risk Factors, Health Disparities, and Future Projections

Rashmi Khanijau *¹, Mona Rajiv Kukkar ², Ena Trehan ³, Priya Singh ⁴

¹ Department of Pharmacology, Mahatma Gandhi College of Pharmaceutical Sciences, Tonk Road, 302022, Jaipur, Rajasthan, India.

² Department of Pharmacognosy, Mahatma Gandhi College of Pharmaceutical Sciences, Tonk Road, 302022, Jaipur, Rajasthan, India.

³ Singhania University, Pacheri Kalan, Bari, Rajasthan 333515, India.

⁴ Department of Pharmacy, Mahatma Gandhi College of Pharmaceutical Sciences, Tonk Road, 302022, Jaipur, Rajasthan, India.

 

HIGHLIGHTS OF REVIEW ARTICLE 

• The global prevalence of diabetes mellitus is rapidly increasing, driven by urbanization, aging populations, and lifestyle changes, with a disproportionate burden in low- and middle-income countries.
• Type 2 diabetes accounts for the majority of cases, while type 1 and gestational diabetes are also rising, contributing significantly to overall disease burden and long-term complications.
• Major risk factors such as obesity, physical inactivity, unhealthy diet, and genetic susceptibility play a critical role, alongside significant socioeconomic and regional health disparities.
• Nanocarrier-based drug delivery systems offer a promising approach for diabetes treatment by enhancing drug stability, targeted delivery, and therapeutic efficacy, thereby improving glycemic control and patient outcomes.
• Emerging advancements, including clinical trials, patent innovations, and nanocarrier-based drug delivery systems, offer promising future strategies for improved diabetes management and outcomes.

GRAPHICAL ABSTRACT

Graphical Abstract: Schematic overview of global trends and burden of diabetes mellitus (DM), highlighting epidemiology, key risk factors, health disparities, disease burden, and emerging therapeutic strategies including nanocarrier-based drug delivery systems.

 

 

Diabetes mellitus is a chronic metabolic disorder which results in permanent high blood sugar levels due to defective insulin production or insulin function or both of these factors and it has become one of the most formidable global public health challenges of the twenty-first century¹. The existing global diabetes situation shows continuous unsafe growth of diabetes cases which affects all age groups and all regions because urbanization progresses and people adopt less active lifestyles and they eat less healthy food and the population ages and obesity rates and metabolic syndrome rates increase^2-3. Diabetes used to be seen as a condition which affected only high-income nations but now the disease impacts more people in low- and middle-income countries because these countries lack sufficient healthcare systems and proper diagnostic methods and effective treatment programs. Diabetic disease affects hundreds of millions of people worldwide with type 2 diabetes mellitus being the most common form of the disease while type 1 diabetes and gestational diabetes cause significant health issues for children and adolescents and pregnant women⁴. The global diabetes burden is further compounded by high rates of undiagnosed disease, delayed initiation of therapy, and poor glycemic control, which together produce a broad range of acute and chronic complications that include cardiovascular disease, nephropathy, neuropathy, retinopathy, and higher risk of infectious diseases, which together result in increased rates of early death and disability-adjusted life years and rising healthcare expenses. The worldwide distribution of diabetes shows significant differences between regions because Southeast Asia, the Western Pacific, the Middle East, and Africa show fast rising diabetes rates, while high-income regions experience increasing diabetes-related health problems that stem from their aging citizens and extended disease duration, which creates substantial health disparities that result from differences in socioeconomic status and healthcare accessibility and the effects of government policies^5-6.

The historical treatment methods for diabetes required patients to control their eating habits and their daily activities until scientists discovered insulin therapy which changed how doctors treated type 1 diabetes and severe hyperglycemia. The introduction of oral antidiabetic medications which included sulfonylureas and biguanides led to enhanced diabetes treatment methods that established better blood sugar management results for type 2 diabetes patients^7-8. The introduction of new drug classes to diabetes treatment during the past 30 years has transformed the field because glucagon-like peptide-1 receptor agonists and sodium–glucose cotransporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors provide better blood sugar control and heart and kidney health advantages⁹. Concurrently, advancements in medical technology, including continuous glucose monitoring systems, insulin pumps, and digital health platforms, have enhanced personalized care and patient self-management; however, access to these innovations remains uneven across regions, reinforcing existing inequities¹⁰. 

International organizations including the World Health Organization and International Diabetes Federation and national regulatory bodies establish evidence-based frameworks which guide diabetes prevention and diagnosis and treatment and complication screening while they monitor antidiabetic drug safety and effectiveness through regulatory procedures and post-marketing monitoring¹¹. A complete review of existing research stands as an immediate need because persistent health inequalities and changing treatment methods and an expanding worldwide health crisis require it. The present review aims to evaluate global DM trends and its associated burden through the analysis of epidemiological data which includes regional and socioeconomic differences and major risk factors and disease burden metrics while the review examines ongoing clinical trials and patent developments to showcase new medical and technological progress. Furthermore, this review addresses key gaps in detection, treatment, and healthcare delivery, and discusses current challenges, limitations, and future perspectives to inform research priorities, clinical practice, and policy development, ultimately contributing to more effective, equitable, and sustainable strategies for mitigating the global impact of DM^12-13.

The article shows how different countries of the world experience diabetes according to their geographical location and their population growth. The study shows that urbanization and population aging and sedentary lifestyles and unhealthy dietary habits have created a major increase in diabetes cases which affects low- and middle-income countries more than other regions. The review provides a complete understanding of the global diabetes situation because it shows how type 2 diabetes predominates while type 1 diabetes and gestational diabetes show emerging health problems. The article assesses how the world diabetes epidemic spreads through its main risk factors which show different effects on various population groups. The study shows that diabetes mellitus develops through multiple pathways which healthcare profession need to understand because metabolic factors and genetic factors and environmental factors and behavioral factors such as obesity and inactivity and poor diet and socioeconomic status affect its development. Lastly, this review provides insights into emerging advancements in nanocarriers and future perspectives in diabetes management, including ongoing clinical trials, patent developments, and innovative therapeutic strategies such as nanocarrier-based drug delivery systems. It also discusses current challenges and limitations in detection, treatment, and healthcare delivery, while emphasizing the need for integrated, patient-centered approaches. 

The worldwide prevalence and incidence of diabetes mellitus has become one of the fastest expanding noncommunicable diseases which affects people of all ages and all parts of the world. The rapid growth of current urban areas together with the increasing elderly population and the widespread adoption of inactive living and poor eating patterns constitutes the main reasons behind this rising trend^13-15. The global distribution of diabetes shows significant differences between regions because low- and middle-income countries lack adequate medical facilities and their populations experience delays in diabetes diagnosis. The increasing age of diabetes onset toward younger people especially with type 2 diabetes will create more extended periods of illness according to research findings¹⁶. A detailed overview of prevalence, incidence, and temporal trends of DM is summarized in Table 1.

Diabetes mellitus has developed into the quickest expanding noncommunicable disease throughout the world because its occurrence and new cases keep increasing without interruption since the past several decades. Global estimates show that diabetes has affected more people than before because population growth and demographic aging and urbanization and changes in eating habits and physical activity have combined to create this situation¹⁷. The analysis of time-based patterns shows that diabetes has spread faster in developing regions than it has in developed areas because of differences between the two regions in their medical system availability and their ability to identify diabetes and their methods for preventing the disease. The overall diabetes prevalence continues to grow because more people with diabetes now live longer even though some high-income countries have begun to show steady rates of new cases. Notably, the onset of diabetes is occurring at younger ages, particularly for type 2 diabetes, leading to longer disease duration and a higher lifetime risk of complications. These trends collectively underscore the escalating global burden of diabetes and the urgent need for strengthened surveillance and preventive interventions^18-19.

2.2 Type-Specific Epidemiological Patterns

Different types of diabetes mellitus exhibit distinct patterns of epidemiological spread. Type 2 diabetes mellitus represents the most common diabetes form which links to several preventable risk factors that include obesity and physical inactivity and poor dietary practices and socioeconomic disadvantages. The disease shows its highest prevalence within urban populations who experience fast-paced changes to their traditional ways of life. The incidence of Type 1 diabetes mellitus has shown an upward trend in multiple areas especially among children and adolescents which indicates that environmental and immunological and genetic elements participate in its development. The worldwide occurrence of gestational diabetes mellitus is rising because women are having children at older ages while their obesity rates are increasing and the condition creates long-term health dangers because it raises the risk of future type 2 diabetes development in mothers and their children.  Understanding these type-specific patterns is critical for designing targeted prevention, screening, and management strategies that address the diverse and evolving nature of the global diabetes epidemic^21-22.

The global trends of DM highlight an escalating public health concern with wide-ranging implications for healthcare systems and economic stability. The increasing prevalence, coupled with earlier onset and prolonged disease duration, underscores the urgent need for effective prevention and control strategies. Strengthening surveillance systems, promoting lifestyle modifications, and ensuring early diagnosis are essential to curb the rising trend of diabetes^23-24. The data presented in Table 1 emphasize the critical need for coordinated global efforts to address this growing epidemic.

The global distribution of DM exhibits significant regional variations which show pronounced health disparities because different population groups experience different socioeconomic conditions and healthcare system capabilities and their lifestyles and genetic factors. The diabetes burden is growing in low- and middle-income countries because people in these regions lack access to early diagnosis and preventive methods and effective treatments which increases their risk of developing complications and dying from the disease^25-26. High-income regions possess superior healthcare systems yet they still encounter difficulties because their populations grow older and people develop health problems through their daily activities. The world shows uneven disease outcomes because urban-rural divides and gender differences and ethnic backgrounds and income brackets create distinct health outcomes for different population groups^27-28. A comprehensive overview of regional prevalence patterns, contributing factors, and associated health disparities is presented in Table 1.

3.1 Continental and Regional Variations

The distribution of diabetes mellitus throughout the world shows distinct regional and continental differences which emerge from varying demographic patterns and economic growth and cultural behaviors and genetic risk factors and medical service availability in different areas. The regions of South-East Asia and the Western Pacific and the Middle East study area face diabetes prevalence rates which increase at the fastest pace because of urban development and changes in their dietary habits and obesity levels^29-30. The high-income areas of North America and Europe show persistent diabetes rates because their populations have stopped experiencing new cases but their diabetes prevalence remains high. Sub-Saharan Africa currently shows lower diabetes rates but the region experiences a rapid increase in diabetes cases because of two factors: underdiagnosis and limited access to medical services. The countries of Latin America and the Caribbean show different levels of diabetes prevalence which exist between two extreme ends of the spectrum throughout the region. These regional variations underscore the complex interplay between environmental, behavioral, and systemic factors shaping the global diabetes burden and highlight the need for region-specific surveillance and intervention strategies^31-32.

3.2 Socioeconomic and Demographic Inequities

Socioeconomic and demographic inequities work as the primary factors which determine how different populations will experience diabetes risk and disease progression and their final health results. People who belong to lower socioeconomic groups face higher rates of health problems because they cannot reach essential resources such as healthy food and safe places to exercise and medical care and programs that offer preventive health screenings³³. The difference between urban and rural areas leads to increased health problems because urban residents develop more health conditions through their inactive lifestyles while rural residents deal with medical problems because they do not receive timely diagnosis or proper treatment. The two factors of age and gender create different diabetes pattern variations because older people show higher diabetes rates while women face special diabetes challenges that stem from gestational diabetes and their duties as caregivers. Most regions show higher diabetes risk and worse health results among ethnic and minority groups because they face both systemic discrimination and obstacles to healthcare access.  Collectively, these disparities contribute to unequal distribution of diabetes-related morbidity and mortality and emphasize the importance of equity-focused public health policies and culturally tailored interventions to reduce the global impact of DM^34-35.

 

 

Table 1: Regional Distribution and Health Disparities in DM^36-38

Region / Continent	Diabetes Prevalence Trend	Key Contributing Factors	Major Health Disparities
North America	High and steadily increasing	Obesity, sedentary lifestyle, aging population	Socioeconomic and ethnic disparities; unequal access to advanced care
Europe	High but relatively stabilized in some countries	Aging population, dietary patterns, lifestyle factors	East–West and socioeconomic inequities in healthcare access
South-East Asia	Rapidly increasing	Urbanization, dietary transition, genetic susceptibility	High rates of undiagnosed diabetes; limited preventive care
Western Pacific	Very high and rising	Rapid economic growth, lifestyle changes	Urban–rural healthcare gaps; rising youth-onset diabetes
Middle East & North Africa	Among the fastest-growing globally	Obesity, physical inactivity, cultural dietary habits	Gender-related and healthcare access disparities
Latin America & Caribbean	Moderate to high with regional heterogeneity	Urbanization, socioeconomic transition	Inequities linked to income level and healthcare coverage
Sub-Saharan Africa	Currently lower but rapidly increasing	Urbanization, changing diets, limited screening	High underdiagnosis rates; inadequate healthcare infrastructure
Oceania (Pacific Islands)	Extremely high in select populations	Genetic predisposition, obesity, nutrition transition	Geographic isolation; limited access to specialized care

 

 

The global diabetes burden gets determined by regional socioeconomic differences that exist across different areas of the world. Targeted public health interventions together with better healthcare access and region-specific prevention and management strategies are necessary to address these inequities. The healthcare system needs strengthening while public awareness needs promotion together with the development of culturally suitable interventions to achieve better health results and reduce health disparities⁴⁰. The data summarized in Table 1 highlight the need for equitable and sustainable approaches to effectively combat the global diabetes epidemic.

Nanocarrier-based drug delivery systems have developed into a modern treatment method which effectively controls diabetes mellitus because it overcomes the shortcomings found in traditional diabetes medications which include their low bioavailability and quick breakdown and their lack of target distribution and their associated adverse effects from high dosages. The nanoscale systems which contain liposomes and niosomes and polymeric nanoparticles and solid lipid nanoparticles and micelles provide improved drug stability together with controlled sustained drug release and better pharmacokinetic performance and targeted tissue delivery which includes pancreatic β-cells and liver and skeletal muscle^41-42. The nanocarriers make it possible to transport various medical substances which include insulin and oral hypoglycemic drugs and peptides and phytoconstituents to enhance treatment results while making it easier for patients to follow their medical regimens. Surface modification together with nanocarrier functionalization developments now enables precise target delivery while diminishing overall body toxicity^43-45.  A comprehensive classification and comparative analysis of various nanocarriers, including their drug loading capacity, composition, preparation techniques, and therapeutic outcomes, are summarized in Table 2.

 

 

 

Table 2: Classification and Characteristics of Nanocarriers Used in Diabetes Management with Emphasis on Drug Loading, Composition, Preparation Methods, and Therapeutic Efficacy

Type of Nanocarriers	Drug/API	Compositions	Type of Diabetes/ Role in Diabetic	Method of preparation	Research Outcomes	Ref.
Polymeric nanoparticles (Eudragit-based SIT-NPs)	Sitagliptin (SIT)	Eudragit RL100 (polymer)+Tween 80 (surfactant)	Anti-diabetic therapy (prolonged glycemic control; likely Type 2 Diabetes management via DPP-4 inhibition)	Combination of solvent evaporation and nanoprecipitation techniques with statistical optimization	Particle size: 135–193 nm; Drug loading: 6.3–8.8%; Sustained release (24 h); Enhanced release and permeation; Spherical smooth morphology; Prolonged glucose reduction; Stable (~488 days).	[46]
Solid Lipid Nanoparticles (SLNs)	Gliclazide (GLZ)	Glyceryl behenate (Compritol® 888 ATO) + Poloxamer 188 + Trehalose dihydrate	Type 2 Diabetes; enhanced oral bioavailability, prolonged glycemic control, improved anti-diabetic efficacy	Ultrasonication technique followed by freeze-drying; optimized using 2×3 factorial design	Particle size: ~246 nm; PDI: ~0.48; Spherical particles; Biphasic release; ~5× bioavailability; Improved efficacy; Prolonged release; Safe.	[47]
Liposomes (oral liposomal formulation)	Sitagliptin	Soy lecithin + Cholesterol	Type 2 Diabetes; enhanced oral bioavailability and improved antihyperglycemic activity	Thin-film hydration technique	Particle size: ~40 nm; Zeta potential: ~40 mV; Drug release: ~88% (8 h); First-order kinetics; No interaction; Enhanced efficacy; Sustained effect (~4 h).	[48]
Liposomes (HDCA-modified liposomes)	Metformin + Hyodeoxycholic acid (HDCA)	Metformin + Hyodeoxycholic acid + Liposomal components (phospholipids/cholesterol-like structure)	Type 2 Diabetes; enhanced bioavailability, reduced side effects, improved hypoglycemic effect, glucose regulation	Thin-film dispersion method	Improved glucose tolerance; Reduced blood glucose; Controlled oxidative stress; Liver protection; Enhanced efficacy; Optimal (1:1) ratio; High HDCA ↓ drug loading.	[49]
Liposomes in hydrogel	Resveratrol	Resveratrol (RV) + Phospholipids + Cholesterol + Carbopol 940 (1%) + Triethanolamine + Purified water	Diabetic foot wounds (DFUs)	thin-film hydration method	RV-loaded liposomes in hydrogel-based wound dressing significantly accelerate wound healing in diabetic foot ulcers by restoring the altered wound healing process in diabetics.	[50]
Long-circulating liposomes (PEGylated liposomes, PLLs)	Polydatin	Lecithin + DSPE-PEG2000 + Cholesterol	Type 2 Diabetes (obese T2DM); sustained release, enhanced bioavailability, improved antidiabetic efficacy	Membrane dispersion method (orthogonal optimization)	Small uniform particles; High encapsulation; Stable; Sustained release; Enhanced uptake; Prolonged circulation; Reduced glucose & lipids; Lower oxidative stress	[51]
Liposomes (ethanol/propylene glycol-based nasal liposomes, ILEP)	Isoxsuprine	Phospholipid + Cholesterol + Ethanol + Propylene glycol	Diabetes-associated ischemic stroke; improved drug delivery, targeting, and neuroprotection	Optimized liposomal formulation (Design Expert-based optimization) for nasal delivery	Improved permeation & targeting; Sustained drug delivery; Enhanced neurological outcomes; Reduced neuronal damage & vascular congestion; Prevented stroke severity in diabetic model	[52]
Nanoparticles	Chitosan alginate	Chitosan + Sodium alginate + Glacial acetic acid + Sodium hydroxide + Purified water	diabetic and non-diabetic pressure ulcers	Modified ionic gelation metho.	Chitosan alginate nanoparticles offer a promising platform for diabetic and non-diabetic wound healing applications.	[53]
Metallic nanoparticles (Green-synthesized AgNPs & FeNPs)	Polyherbal formulation (Mehani-derived phytochemicals)	Polyherbal extract (reducing/capping agents) + Silver ions / Iron (zero-valent)	Anti-diabetic (hyperglycemia management via α-amylase inhibition) + Antioxidant activity	Green synthesis (biogenic reduction using polyherbal formulation)	Size: AgNPs (60–80 nm), FeNPs (40–60 nm); Characterized (UV, FTIR, XRD, SEM); Strong antioxidant activity; α-amylase inhibition: ~65% (AgNPs), ~70% (FeNPs); FeNPs superior.	[54]
Polymeric nanoparticles (PLGA-based NPs)	Metformin (MTF)	PLGA polymer	DM (likely Type 2); enhanced oral bioavailability and antidiabetic efficacy	Solvent evaporation method	Particle size: ~178 nm; Zeta potential: ~−22.6 mV; Entrapment: ~84.7%; Biphasic release (~82.5%/24 h); ~2.6× bioavailability; ~62.8% glucose reduction; Improved pancreatic histology	[55]

 

 

Nanocarrier-based therapeutic strategies provide a new treatment method for diabetes which solves essential problems that traditional drug delivery systems face. The system demonstrates potential for both diabetes types because it delivers improved BA and targeted drug delivery with controlled release which enhances treatment results. The existing preclinical and clinical data show positive results yet researchers must solve multiple issues related to manufacturing at scale and maintaining safety over time and obtaining regulatory endorsement and proving cost efficiency. The future research will advance their clinical applications while enhancing diabetes treatment results through its focus on developing advanced nanocarrier systems and personalized medical approaches and their use with new medical technologies^57-58.

Diabetes mellitus represents a serious worldwide health problem which increases both death rates and disability rates and generates economic burdens for healthcare systems. The chronic and progressive nature of diabetes has led to increasing diabetes-related deaths because complications of the disease cause both cardiovascular disease and nephropathy and neuropathy and infections^59-60. Diabetes creates a major disability burden because it results in two different disability measures which include disability-adjusted life years and years lived with disability. The economic consequences of diabetes extend to direct medical expenditures for treatment and hospitalization and to indirect financial losses from decreased work ability and disability and early death^61-62. These factors collectively highlight the extensive and multifaceted burden of diabetes on individuals, healthcare systems, and global economies.

5.1 Mortality Patterns

Diabetes mellitus serves as a significant worldwide death cause because it directly kills people and serves as a danger that triggers multiple fatal diseases which include heart disease and chronic kidney disease and infectious diseases. The diabetes-related death rate has shown a consistent upward trend during the past several decades because people now develop diabetes at younger ages and live with the disease for extended periods. The global patterns of mortality show major differences between regions, as low- and middle-income countries experience higher diabetes-related death rates due to their common practice of diagnosing diabetes at a later stage and their restricted access to crucial medications and their insufficient capacity to handle the disease⁶³. High-income regions report better health outcomes because their residents have access to healthcare services which enables them to receive timely treatment and proper care for their multiple health conditions, but their total death count remains elevated because of their growing elderly demographic. Age- and sex-specific differences in mortality further highlight disparities, with older adults and individuals from socioeconomically disadvantaged groups experiencing disproportionately higher risk of diabetes-related death. These mortality trends emphasize the critical role of early detection, effective treatment, and integrated management strategies in reducing diabetes-associated deaths⁶⁴.

5.2 Disability-Adjusted Life Years, Years Lived with Disability, and Economic Costs Diabetes-related DALYs have increased globally, driven primarily by a rise in YLDs rather than years of life lost, because people now survive longer yet live with chronic health problems. The major disability-causing health problems arise from microvascular and macrovascular complications, which include neuropathy, retinopathy, nephropathy, and cardiovascular disease⁶⁵. The economic impact of diabetes extends beyond direct medical expenses for outpatient treatment and hospital stays and medications and complication management because it also includes indirect costs from lost work time and disability and early death. The economic burden on low- and middle-income countries becomes excessive because healthcare costs take up a substantial portion of household income, which leads to increased poverty and health inequalities. Collectively, the growing disability and economic costs of diabetes highlight the urgent need for cost-effective prevention strategies, early intervention, and sustainable health system investments to mitigate the long-term global impact of the disease^65-66.Bottom of Form

Diabetes mellitus creates a substantial burden that extends beyond its clinical effects because it results in high rates of death and permanent disabilities and creates major financial effects. The increasing diabetes burden in low-income and middle-income nations requires immediate development of affordable effective diabetes prevention and treatment programs⁶⁷. The healthcare system requires three essential elements which include better detection methods and expanded medical service access and creation of specific programs that will help reduce health complications. The healthcare system needs both integrated policy solutions and continuous financial support to decrease diabetes-related economic burdens while improving public health outcomes⁶⁸.

The worldwide increase in diabetes mellitus occurs through various metabolic and genetic and behavioral and dietary and environmental and social factors which determine how people develop and advance their illnesses. Obesity especially central body fat distribution represents the primary reversible health hazard which researchers established as a cause of insulin resistance and persistent low-level inflammation and pancreatic β-cell damage^69-70. Diabetes develops through multiple pathways which share biologic mechanisms that include dyslipidemia and hypertension and metabolic syndrome as risk factors (Fig. 1). Genetic predisposition also plays an important role, as evidenced by familial clustering and the identification of multiple susceptibility loci associated with insulin secretion and glucose metabolism⁷¹.

 

 

Figure 1: Mechanistic overview of the pathophysiology of DM illustrating the interplay between insulin deficiency and insulin resistance leading to impaired glucose utilization. The figure highlights key metabolic alterations including hyperglycemia, enhanced lipolysis, increased protein catabolism, and associated complications such as diabetic ketoacidosis, glycosuria, polyuria, and systemic metabolic imbalance across major organs.

 

Genetic risk factors by themselves cannot account for the worldwide rise in diabetes cases since they require environmental elements and human behavioral patterns for their explanation. People who have different lifestyle choices show different levels of risk for developing diabetes according to research studies^72-73. The combination of physical inactivity and sedentary lifestyles together with urban development and technological progress has resulted in a nationwide surge of insulin resistance (Fig. 2). People who use tobacco and drink too much alcohol develop metabolic disorders that lead to problems with their blood sugar control. The two main causes of diabetes risk which people often overlook are psychosocial stress and sleeping problems which occur together with shift work in urban and industrial areas medical work fields⁷⁴. These lifestyle-related factors frequently cluster within disadvantaged socioeconomic groups, amplifying health inequities and accelerating disease burden in vulnerable populations^73-74.

 

 

Figure 2: Schematic illustration depicting the mechanistic interplay between insulin resistance and gut microbiota dysbiosis, highlighting how altered intestinal bacterial composition accelerates metabolic dysfunction, promotes inflammation, and contributes to the progression of liver damage, including non-alcoholic fatty liver disease (NAFLD).

 

 

The global diabetes epidemic experiences its most significant growth through dietary patterns which result in worldwide health issues. People in various regions have changed their eating habits by choosing energy-dense ultra-processed foods which contain refined carbohydrates and added sugars and saturated fats and sodium instead of their traditional nutrient-rich diets. People who drink high amounts of sugar-sweetened beverages but eat very little dietary fiber and whole grains and fruits and vegetables usually experience higher chances of developing diabetes^75-76. Globalization of food systems together with food marketing campaigns and restricted access to inexpensive healthy food options especially affects people in low- and middle-income countries which leads to these dietary changes. Worldwide diabetes risk escalates because of environmental changes and demographic shifts. Scientific research increasingly links air pollution exposure together with endocrine-disrupting chemicalsand obesogenic built environments to metabolic health problems. The world population now faces its primary demographic challenge because older people face higher diabetes risk through insulin resistance and reduced β-cell function and long-term exposure to metabolic health problems⁷⁷. The convergence of these metabolic, behavioral, environmental, and aging-related risks highlights the multifactorial nature of DM and underscores the need for comprehensive, multisectoral prevention strategies to effectively curb its growing global burden^77-78.

DM research today shows active progression through its ongoing clinical trials and patent developments. Clinical studies currently investigate new drug treatments advanced insulin products and combination treatment methods which include nanocarrier drug delivery systems and digital health solutions^79-80. The trials seek to enhance glycemic control while they work to treat related health issues which include cardiovascular and renal complications. The patent system currently focuses on creating new drug development methods and delivering technologies which improve treatment results and make it easier for patients to follow their medical regime⁸⁰. A detailed overview of recent and ongoing clinical trials, including study design, interventions, and status, is presented in Table 3, while recent patent developments and technological advancements in diabetes management are summarized in Table 4.

 

 

Table 3: Summary of Current Clinical Trials in DM Highlighting Study Design, NCT Identification Number, Recruitment Status, Interventions, Initiation Timeline, and Key Descriptive Outcomes

Study Title	Study Type	NCT     Number	Status	Interventions	Start Date
A Study of CX11 Tablets in Patients With Type 2 Diabetes Mellitus	Interventional	NCT07340320	Phase-2	Drug: CX11 Other: Placebo	2026-02-05
Short- and Long-Term Effects of Whole-Body Photobiomodulation in Type II Diabetes Patients: A Protocol for a Controlled Clinical Trial (PBM)	Interventional	NCT07047248	Not Applicable	Device: PBM Other: Placebo PBM	2025-08-30
Effects of Core Strengthening Exercises With Diapgragmatic Breathing Versus Core Strengthening Exercises With Pilate Breathing in Diabetes Type II Patients	Interventional	NCT07290231	Not Applicable	Other: Core Strengthening with Diaphragmatic Breathing Other: core strengthening with pilate breathing	2025-08-06
A Participatory Approach to Support Glucose Tolerance Tracking in Real-Life of Patients With Type 2 Diabetes (GluToTrack)	Interventional	NCT06864546	Not Applicable	Behavioral: Physical activity intervention	2025-05
A Clinical Trial to Evaluate the Food Effect of CKD-379 (CKD-379)	Interventional	NCT06652971	Phase-1	Drug: CKD-379	2024-11-05
Efficacy and Safety of Piemonte Association in the Treatment of Type II DM (PIEMONTE)	interventional	NCT05028140	Phase 3	Drug: PIEMONTE Other: PIEMONTE PLACEBO Drug: EMPAGLIFLOZIN	2024-10-08
A Clinical Trial to Evaluate the Food Effect of CKD-378	Interventional	NCT06386328	Phase-1	Drug: CKD-378, QD, PO	2024-05-03
Evaluate HM-002-1005 in Subjects With Type 2 Diabetes Mellitus	Interventional	NCT06498284	Phase-1	Drug: HM-002-1005	2024-04-25
Effects of Eccentric Training on Glycemic Control and Quality of Life in Patients With Type II Diabetes Mellitus	interventional	NCT06387550	Not Applicable	Procedure: Eccentric Training	2024-03-20
Relative Hand Grip Strength and Functional Fitness in Diabetic Patient in Egypt	Interventional	NCT06645418	Not Applicable	Diagnostic Test: relative Hand grip strength Diagnostic Test: senior fitness test	2023-10-15
Study to Evaluate the Safety and Pharmacokinetics of CKD-379	Interventional	NCT05952219	Phase 1	Drug: CKD-379 Drug: D759+D745+D029+D150	2023-06-02
Effect of Coherent Breathing on Elderly Quality of Life	Interventional	NCT05767372	Not Applicable	Other: Coherent Breathing Exercise Device: Inspiratory muscle training	2023-03-01
Pharmacokinetics and Safety/Tolerability of CKD-379	Interventional	NCT05719155	Phase 1	Drug: CKD-379 Drug: D759+D745+D150	2023-02-27
Development and Exploration of the Effectiveness and Feasbility of a Digital Intervention for Type 2 Diabetes Mellitus (DEsireD)	Interventional	NCT05364476	Not Applicable	Behavioral: 16 weeks digital intervention	2022-04-11
Dual Add-on Therapy in Type 2 Diabetes Poorly Controlled With Metformin Monotherapy	interventional	NCT04667143	Phase 3	Drug: Retagliptin, Henagliflozein, metformin XR	21-01

 

Table 4: Overview of Current Patents in DM Highlighting Innovative Therapeutic Strategies, Drug Delivery Systems, and Emerging Nanotechnology-Based Approaches

Entitle	Application no./Grant No	Authors	Filling date	Grant/ Publication date
System for Assessing Global Wellness	US19/051,210	Jill Wade	2025-02-12	2025-07-03
Method for inducing weight loss in a type 2 diabetes mellitus patient	US18/987,056	Elisabeth Niemoeller, Louise Silvestre	2024-12-19	25-05-01
Fgf21 variants	US18/932,818	Mark Sommerfeld, Thomas Langer	2024-10-31	2025-05-29
Treatment for diabetes in patients inappropriate for metformin therapy	US18/921,039	Klaus Dugi, Eva Ulrike, Ruth Anne	2024-10-21	2025-10-09
Methods and Compositions for Oral Administration of Proteins	US18/921,419	Miriam Kidron	2024-10-21	2025-09-11
Cardio- and renoprotective antidiabetic therapy	US18/907,618	Odd-Erik, Maximillan Von	2024-10-07	2025-01-23
Fusion proteins	US18/756,062	David Bruce Baldwin, John Michael Beals	2024-06-27	2025-01-30
Treatments for Diabetes Mellitus and Obesity	US18/599,902	Pankaj PasrichaLiansheng Liu	2024-03-08	2024-06-27
Method of treating diabetes type 2 by administering ultrarapid acting insulin	US18/593,204	Peter Richardson, Robert A. Baughman	2024-03-01	2024-06-20
Sdc-2 exosome compositions and methods of isolation and use	US18/425,997	Stephen J. Elliman, Jack Kavanaugh	2024-01-29	24-07-25
Pharmaceutical composition, methods for treating and uses thereof	US18/422,333	Uli Christian, Odd-Erik	2024-01-25	2024-05-16
Methods and systems for determining risk of a pregnancy complication occurring	US18/136,805	Claire Trelford Roberts, Shalem Yiner-Lee	2023-04-19	2024-02-01
Implantable therapeutic delivery system and methods thereof	US18/396,941	Minglin Ma, James A. Flanders	2023-12-27	2024-12-05
Diabetes risk early warning method based on big data analysis	CN202311506972.3A		2023-11-14	2024-01-26
Device for non-invasive detection of skin problems associated with diabetes mellitus	US17/752,755	Mike Van Snellenberg, Anne Weiler	2022-05-24	2022-09-08
Viral vectors for the treatment of diabetes	US17/384,533	Cristina Mallol Dominguez	2021-07-23	2022-06-16
Polymeric bile acid nanocompositions targeting the pancreas and colon	AU2020267191A	Tarek M. Fahmy.Dongin Kim	2020-11-10	2022-08-18

 

 

The growing number of clinical trials and patent applications demonstrates that researchers continue their work to develop innovative solutions for diabetes management through their interdisciplinary research efforts. The new developments create potential treatment options but face major challenges which include three main obstacles that prevent widespread implementation and use of the solutions^81-82. The process of transferring research breakthroughs into practical medical applications needs all parties which include researchers and healthcare professionals and policy makers and business leaders to work together. The information in Table 3 and Table 4 shows that new treatment methods continue to develop, which will lead to better health results for patients and improved diabetes management worldwide⁸³.

The diabetes care system still suffers from major treatment gaps which extend from initial patient assessments through to ongoing patient treatment. A significant number of people who have diabetes remain undiagnosed worldwide because they cannot access regular screening tests and the existing methods to identify their risk of diabetes do not work together with their social and cultural background and their type 2 diabetes develops without showing any symptoms during its initial stages. The highest detection gaps exist in regions that experience both low and middle economic development because their healthcare systems lack sufficient resources and their preventive health services do not receive adequate funding^84-85. After patients receive their diagnosis, treatment gaps develop because people cannot obtain necessary medication and insulin and self-monitoring equipment and new digital health solutions. The existence of multiple insurance plans together with high treatment expenses and supply chain interruptions creates additional challenges which prevent patients from adhering to therapy and maintaining their medical treatment. Healthcare system-level challenges-including shortages of trained endocrinologists and diabetes educators, inconsistent implementation of evidence-based clinical guidelines, limited integration of diabetes care into primary health systems, and poor coordination between levels of care-significantly hinder optimal disease control⁸⁶. The lack of proper patient education and lifestyle counseling and long-term follow-up programs leads to poor glycemic control and increases the risk of developing microvascular and macrovascular diseases. The existing gaps in health systems require immediate action to develop robust health systems and scalable screening methods and affordable treatment options and patient-centered care systems which will help to reduce the rising global diabetes mellitus burden^86-87.

The scientific community has achieved significant progress toward understanding diabetes mellitus epidemiology and treatment yet they still need to solve several persistent critical problems in this field. The primary obstacle exists because researchers worldwide face difficulties accessing high-quality data from developing nations which suffer from both underdiagnosis problems and their inconsistent monitoring systems and their lacking medical facilities. The different diagnostic criteria and reporting standards together with the various study methods used by researchers create difficulties for international researchers who need to make cross-country comparisons and conduct trend analyses⁸⁸. The research field currently shows inadequate representation of vulnerable groups which includes people from rural areas and minority ethnic communities and individuals who come from economically disadvantaged backgrounds, which leads to restricted research applicability and hides actual health disparity between different population groups. The clinical treatment of diabetes problems because its causes include genetic factors and environmental influences and human behavioral patterns. Future perspectives should prioritize the integration of standardized, high-quality global surveillance systems which digital health technologies and real-time data analytics systems will support. The scientific community requires population-based studies which track participant health over time and include genomic data, metabolomic data, and environmental data to investigate disease mechanisms and risk assessment methods^89-90. The healthcare system requires primary care improvements which combine better screening methods and personalized treatment programs to reduce health disparities. The global health crisis requires artificial intelligence and machine learning to create predictive models while policy interventions need to target both lifestyle changes and the social factors that affect health. The research field requires multidisciplinary teams to create sustainable diabetes prevention and control methods which combine clinical research and public health policy and technological innovation.

CONCLUSION

`The worldwide health issue of diabetes mellitus diabetes now causes severe medical problems and economic damages and social difficulties that continue to grow. The increasing number of cases in different demographic groups shows how demographic changes and urban development and changes in human behavior and genetic factors work together to create this health issue. The research demonstrates that although people now understand diabetes better and there are new treatments available the healthcare system still lacks efficient ways for patients to receive early treatment and proper diabetes management and fair healthcare system benefits particularly in developing countries. The social and environmental health factors need to be tackled because vulnerable groups bear an unequal health burden. The diabetes epidemic requires a complete integrated solution for its resolution. The public health system needs strengthening while preventive programs which focus on helping people change their behavior should be developed and everyone should have access to inexpensive diagnostic tests and treatments. The health field currently witnesses progress in three key areas which include precision medicine and digital health and data-driven epidemiology. The healthcare systems and policymakers and researchers and communities need to collaborate toward evidence-based practice implementation which will help achieve diabetes mellitus burden reduction goals.

LIST OF ABBREVIAITON

DM: Diabetes Mellitus; DFUs: Diabetic Foot Ulcers; T1DM: Type 1 Diabetes Mellitus; T2DM: Type 2 Diabetes Mellitus; GDM: Gestational Diabetes Mellitus; WHO: World Health Organization; IDF: International Diabetes Federation; GBD: Global Burden of Disease; DALYs: Disability-Adjusted Life Years; YLDs: Years Lived with Disability; YLLs: Years of Life Lost; GLP-1: Glucagon-Like Peptide-1; SGLT-2: Sodium–Glucose Cotransporter-2; DPP-4: Dipeptidyl Peptidase-4; NPs: Nanoparticles; SLNs: Solid Lipid Nanoparticles; RV: Resveratrol; GAGs: Glycosaminoglycans; CS: Chitosan; ALG: Alginate; Mw: Molecular Weight; pKa: Acid Dissociation Constant; cP: Centipoise; BA: Bioavailability. 

Acknowledgements: The authors would like to express their sincere gratitude to their respective institutions for providing the necessary facilities and support to carry out this work. The authors also acknowledge colleagues and peers for their valuable suggestions and constructive feedback during the preparation of this manuscript.

Funding: The authors declare that no specific funding was received for this study from any funding agency in the public, commercial, or not-for-profit sectors.

Conflict of Interest: The authors declare that there is no conflict of interest regarding the publication of this paper.

Author Contributions: All authors contributed significantly have equal contribution to the preparation of this manuscript. All authors have read and approved the final version of the manuscript.

Ethical Approvals: This article does not contain any studies involving human participants or animals performed by any of the authors. Therefore, ethical approval was not required.

Informed Consent: Not applicable.

Data Availability Statement: Data sharing is not applicable to this article as no new data were created or analyzed in this study.

Consent for Publication: Not applicable.

REFERENCES 

1. Saxena S, Saxena R, Singh AP, Maurya NK. Metabolic reasons of diabetes mellitus: an update. Int J Clin Biochem Res. 2024;11:8-11. https://doi.org/10.18231/j.ijcbr.2024.002

2. Nadhiya J, Vijayalakshmi MK, Showbharnikhaa S. A brief review on diabetes mellitus. Journal of Pharma Insights and Research. 2024 Feb 7;2(1):117-21.

3. Powers AC, Niswender KD, Evans-Molina C. Diabetes mellitus: diagnosis, classification, and pathophysiology. Diabetes. 2022;1000:415.

4. Shaikh AA, Kolhatkar MK, Sopane DR, Thorve AN. Review on: Diabetes mellitus is a disease. International Journal of research in Pharmaceutical sciences. 2022 Mar 23;13(1):102-9. https://doi.org/10.26452/ijrps.v13i1.27

5. Mohajan D, Mohajan HK. Basic concepts of diabetics mellitus for the welfare of general patients. Studies in Social Science & Humanities. 2023 Jun 20;2(6):23-31. https://doi.org/10.56397/SSSH.2023.06.03

6. Marruganti C, Suvan JE, D'Aiuto F. Periodontitis and metabolic diseases (diabetes and obesity): Tackling multimorbidity. Periodontology 2000. 2023 Oct 16. https://doi.org/10.1111/prd.12536 PMid:37845800

7. Blagov A, Nedosugova L, Kirichenko T, Sukhorukov V, Melnichenko A, Orekhov A. Mitochondrial dysfunction as a factor of energy metabolism disorders in type 2 diabetes mellitus. Front Biosci (Schol Ed). 2024 Mar 8;16(1):5. https://doi.org/10.31083/j.fbs1601005 PMid:38538341

8. Borovcanin MM, Vesic K, Petrovic I, Jovanovic IP, Mijailović NR. Diabetes mellitus type 2 as an underlying, comorbid or consequent state of mental disorders. World Journal of Diabetes. 2023 May 15;14(5):481. https://doi.org/10.4239/wjd.v14.i5.481 PMid:37273248 PMCid:PMC10236997

9. Aloke C, Egwu CO, Aja PM, Obasi NA, Chukwu J, Akumadu BO, Ogbu PN, Achilonu I. Current advances in the management of diabetes mellitus. Biomedicines. 2022 Sep 29;10(10):2436. https://doi.org/10.3390/biomedicines10102436 PMid:36289697 PMCid:PMC9599361

10. Bodke H, Wagh V, Kakar G, WAGH V. Diabetes mellitus and prevalence of other comorbid conditions: a systematic review. Cureus. 2023 Nov 24;15(11). https://doi.org/10.7759/cureus.49374

11. Siam NH, Snigdha NN, Tabasumma N, Parvin I. Diabetes mellitus and cardiovascular disease: exploring epidemiology, pathophysiology, and treatment strategies. Reviews in Cardiovascular Medicine. 2024 Dec 11;25(12):436. https://doi.org/10.31083/j.rcm2512436 PMid:39742220 PMCid:PMC11683709

12. Garg P, Duggal N. Type 2 diabetes mellitus, its impact on quality of life and how the disease can be managed-a review. Obesity Medicine. 2022 Oct 1;35:100459. https://doi.org/10.1016/j.obmed.2022.100459

13. Grisi DC, Vieira IV, de Almeida Lima AK, de Oliveira Mattos MC, Damê-Teixeira N, Salles LP, De Oliveira LA, Stefani C, do Carmo Machado Guimarães M. The complex interrelationship between diabetes mellitus, oral diseases and general health. Current Diabetes Reviews. 2022 Mar 1;18(3):8-22. https://doi.org/10.2174/1573399817666210322153210 PMid:34225632

14. Balooch Hasankhani M, Mirzaei H, Karamoozian A. Global trend analysis of diabetes mellitus incidence, mortality, and mortality-to-incidence ratio from 1990 to 2019. Scientific Reports. 2023 Dec 11;13(1):21908. https://doi.org/10.1038/s41598-023-49249-0 PMid:38081899 PMCid:PMC10713611

15. Pan C, Cao B, Fang H, Liu Y, Zhang S, Luo W, Wu Y. Global burden of diabetes mellitus 1990-2021: epidemiological trends, geospatial disparities, and risk factor dynamics. Frontiers in Endocrinology. 2025 Jul 1;16:1596127. https://doi.org/10.3389/fendo.2025.1596127 PMid:40666058 PMCid:PMC12259457

16. Nanda M, Sharma R, Mubarik S, Aashima A, Zhang K. Type-2 diabetes mellitus (T2DM): spatial-temporal patterns of incidence, mortality and attributable risk factors from 1990 to 2019 among 21 world regions. Endocrine. 2022 Sep;77(3):444-54. https://doi.org/10.1007/s12020-022-03125-5 PMid:35841511

17. Zhou B, Rayner AW, Gregg EW, Sheffer KE, Carrillo-Larco RM, Bennett JE, Shaw JE, Paciorek CJ, Singleton RK, Pires AB, Stevens GA. Worldwide trends in diabetes prevalence and treatment from 1990 to 2022: a pooled analysis of 1108 population-representative studies with 141 million participants. The Lancet. 2024 Nov 23;404(10467):2077-93.

18. Dedov II, Shestakova MV, Vikulova OK, Zheleznyakova AV, Isakov MA, Sazonova DV, Mokrysheva NG. Diabetes mellitus in the Russian Federation: dynamics of epidemiological indicators according to the Federal Register of Diabetes Mellitus for the period 2010-2022. Diabetes mellitus. 2023 May 14;26(2):104-23. https://doi.org/10.14341/DM13035

19. Yameny AA. Diabetes mellitus overview 2024. Journal of Bioscience and Applied Research. 2024 Sep 28;10(3):641-5. https://doi.org/10.21608/jbaar.2024.382794

20. Hossain MJ, Al‐Mamun M, Islam MR. Diabetes mellitus, the fastest growing global public health concern: Early detection should be focused. Health science reports. 2024 Mar;7(3):e2004. https://doi.org/10.1002/hsr2.2004 PMid:38524769 PMCid:PMC10958528

21. Cheng K, Guo Q, Yang W, Wang Y, Sun Z, Wu H. Mapping knowledge landscapes and emerging trends of the links between bone metabolism and diabetes mellitus: a bibliometric analysis from 2000 to 2021. Frontiers in public health. 2022 Jun 3;10:918483. https://doi.org/10.3389/fpubh.2022.918483 PMid:35719662 PMCid:PMC9204186

22. Bodke H, Wagh V, Kakar G, WAGH V. Diabetes mellitus and prevalence of other comorbid conditions: a systematic review. Cureus. 2023 Nov 24;15(11). https://doi.org/10.7759/cureus.49374

23. Su B, Wang Y, Dong Y, Hu G, Xu Y, Peng X, Wang Q, Zheng X. Trends in diabetes mortality in urban and rural China, 1987-2019: a joinpoint regression analysis. Frontiers in endocrinology. 2022 Jan 17;12:777654. https://doi.org/10.3389/fendo.2021.777654 PMid:35111135 PMCid:PMC8801697

24. Gregory GA, Robinson TI, Linklater SE, Wang F, Colagiuri S, de Beaufort C, Donaghue KC, Harding JL, Wander PL, Zhang X, Li X. Global incidence, prevalence, and mortality of type 1 diabetes in 2021 with projection to 2040: a modelling study. The lancet Diabetes & endocrinology. 2022 Oct 1;10(10):741-60. https://doi.org/10.1016/S2213-8587(22)00218-2 PMid:36113507

25. Bellia A, Meloni M, Andreadi A, Uccioli L, Lauro D. Geographic and ethnic inequalities in diabetes-related amputations. Frontiers in clinical diabetes and healthcare. 2022 Mar 11;3:855168. https://doi.org/10.3389/fcdhc.2022.855168 PMid:36992760 PMCid:PMC10012100

26. Pan C, Cao B, Fang H, Liu Y, Zhang S, Luo W, Wu Y. Global burden of diabetes mellitus 1990-2021: epidemiological trends, geospatial disparities, and risk factor dynamics. Frontiers in Endocrinology. 2025 Jul 1;16:1596127. https://doi.org/10.3389/fendo.2025.1596127 PMid:40666058 PMCid:PMC12259457

27. Yedjou CG, Sims JN, Njiki S, Chitoh AM, Joseph M, Cherkos AS, Tchounwou PB. Health and racial disparities in diabetes mellitus prevalence, management, policies, and outcomes in the United States. Journal of community medicine & public health. 2024 Aug 15;8(3):460. https://doi.org/10.29011/2577-2228.100460 PMid:39697180 PMCid:PMC11654833

28. Nanda M, Sharma R, Mubarik S, Aashima A, Zhang K. Type-2 diabetes mellitus (T2DM): spatial-temporal patterns of incidence, mortality and attributable risk factors from 1990 to 2019 among 21 world regions. Endocrine. 2022 Sep;77(3):444-54. https://doi.org/10.1007/s12020-022-03125-5 PMid:35841511

29. Lobo JM, Kang H, Brennan MB, Kim S, McMurry TL, Balkrishnan R, Anderson R, McCall A, Sohn MW. Regional and racial disparities in major amputation rates among medicare beneficiaries with diabetes: a retrospective study in the southeastern USA. BMJ Public Health. 2023 Dec 12;1(1). https://doi.org/10.1136/bmjph-2023-000206 PMid:38764700 PMCid:PMC11101188

30. Hassan S, Gujral UP, Quarells RC, Rhodes EC, Shah MK, Obi J, Lee WH, Shamambo L, Weber MB, Narayan KV. Disparities in diabetes prevalence and management by race and ethnicity in the USA: defining a path forward. The lancet Diabetes & endocrinology. 2023 Jul 1;11(7):509-24. https://doi.org/10.1016/S2213-8587(23)00129-8 PMid:37356445 PMCid:PMC11070656

31. Alqahtani B, Elnaggar RK, Alshehri MM, Khunti K, Alenazi A. National and regional prevalence rates of diabetes in Saudi Arabia: analysis of national survey data. International Journal of Diabetes in Developing Countries. 2023 Jun;43(3):392-7. https://doi.org/10.1007/s13410-022-01092-1

32. Hossain MJ, Al‐Mamun M, Islam MR. Diabetes mellitus, the fastest growing global public health concern: Early detection should be focused. Health science reports. 2024 Mar;7(3):e2004. https://doi.org/10.1002/hsr2.2004 PMid:38524769 PMCid:PMC10958528

33. Hazar N, Jokar M, Namavari N, Hosseini S, Rahmanian V. An updated systematic review and Meta-analysis of the prevalence of type 2 diabetes in Iran, 1996-2023. Frontiers in public health. 2024 Apr 4;12:1322072. https://doi.org/10.3389/fpubh.2024.1322072 PMid:38638475 PMCid:PMC11025666

34. Syarifuddin S, Samosir W. Characteristics of types of diabetes mellitus II in regional general hospital than rondahaim, simalungun district. Medalion Journal: Medical Research, Nursing, Health and Midwife Participation. 2022 Dec 31;3(4):144-8. https://doi.org/10.59733/medalion.v3i4.64

35. Huang X, Wu Y, Ni Y, Xu H, He Y. Global, regional, and national burden of type 2 diabetes mellitus caused by high BMI from 1990 to 2021, and forecasts to 2045: analysis from the global burden of disease study 2021. Frontiers in public health. 2025 Jan 23;13:1515797. https://doi.org/10.3389/fpubh.2025.1515797 PMid:39916706 PMCid:PMC11798972

36. Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, Stein C, Basit A, Chan JC, Mbanya JC, Pavkov ME. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes research and clinical practice. 2022 Jan 1;183:109119. https://doi.org/10.1016/j.diabres.2021.109119 PMid:34879977 PMCid:PMC11057359

37. Burnside MJ, Williman JA, Davies HM, Jefferies CA, Paul RG, Wheeler BJ, Wiltshire EJ, Anderson YC, De Bock MI. Inequity in access to continuous glucose monitoring and health outcomes in paediatric diabetes, a case for national continuous glucose monitoring funding: a cross-sectional population study of children with type 1 diabetes in New Zealand. The Lancet Regional Health-Western Pacific. 2023 Feb 1;31. https://doi.org/10.1016/j.lanwpc.2022.100644 PMid:36419466 PMCid:PMC9676142

38. Kang PS, Neeland IJ. Body fat distribution, diabetes mellitus, and cardiovascular disease: an update. Current cardiology reports. 2023 Nov;25(11):1555-64. https://doi.org/10.1007/s11886-023-01969-5 PMid:37792133

39. Yom S, Lor M. Advancing health disparities research: the need to include Asian American subgroup populations. Journal of racial and ethnic health disparities. 2022 Dec;9(6):2248-82. https://doi.org/10.1007/s40615-021-01164-8 PMid:34791615 PMCid:PMC8598103

40. Murtaza G, Riaz S, Zafar M, Ahsan Raza M, Kaleem I, Imran H, Al-Harbi AT, Sabouri A, Asim Niaz T, Bashir S. Examining the growing challenge: Prevalence of diabetes in young adults. Medicine International. 2024 Nov 6;5(1):2. https://doi.org/10.3892/mi.2024.201 PMid:39563945 PMCid:PMC11571047

41. Almohmadi NH, Tiwari A, Chaudhary T, Ekta, Sindhu RK, Babu MA, Yassen AS, Alexiou A, Papadakis M, Batiha GE. Nanocarrier-based drug delivery systems: A way to effective diabetes management. BioNanoScience. 2025 Jun;15(2):281. https://doi.org/10.1007/s12668-025-01818-5

42. Singh LS. Developing nanocarrier-based formulations of antidiabetic drugs derived from medicinal plants: A systemic review. Pharmacological Research-Natural Products. 2024 Mar 1;2:100004. https://doi.org/10.1016/j.prenap.2023.100004

43. Kumar D, Singh AK, Kumar A, Singh H, Yadav JP, Kumar P. Bioactive‐Based Nanocarriers for Diabetes. Bioactive‐Based Nanotherapeutics. 2025 Aug 13:389-415. https://doi.org/10.1002/9781394287345.ch12

44. Guo S, Li H. Chitosan-Derived Nanocarrier Polymers for Drug Delivery and pH-Controlled Release in Type 2 Diabetes Treatment. Journal of Fluorescence. 2025 Jun;35(6):3895-904. https://doi.org/10.1007/s10895-024-03810-w PMid:38888657

45. Sarkhel S, Shuvo SM, Ansari MA, Mondal S, Kapat P, Ghosh A, Sarkar T, Biswas R, Atanase LI, Carauleanu A. Nanotechnology-based approaches for the management of diabetes mellitus: an innovative solution to long-lasting challenges in antidiabetic drug delivery. Pharmaceutics. 2024 Dec 9;16(12):1572. https://doi.org/10.3390/pharmaceutics16121572 PMid:39771551 PMCid:PMC11678074

46. Jahangir MA, Khan R, Sarim Imam S. Formulation of sitagliptin-loaded oral polymeric nano scaffold: process parameters evaluation and enhanced anti-diabetic performance. Artificial cells, nanomedicine, and biotechnology. 2018 Oct 31;46(sup1):66-78. https://doi.org/10.1080/21691401.2017.1411933 PMid:29226729

47. Nazief AM, Hassaan PS, Khalifa HM, Sokar MS, El-Kamel AH. Lipid-based gliclazide nanoparticles for treatment of diabetes: formulation, pharmacokinetics, pharmacodynamics and subacute toxicity study. International journal of nanomedicine. 2020 Feb 18:1129-48. https://doi.org/10.2147/IJN.S235290 PMid:32110012 PMCid:PMC7038779

48. Mishra R, Pal R, Khan Z, Sahoo S, Chawra HS, Kumar D. Solid lipid nanoparticles (SLNPs): a state-of-the-art formulation strategy and their applications against tuberculosis (TB) and analgesic effects. Nanoscience & Nanotechnology-Asia. 2025 Jun;15(3):E22106812379362. https://doi.org/10.2174/0122106812379362250602075954

49. Hu M, Gou T, Chen Y, Xu M, Chen R, Zhou T, Liu J, Peng C, Ye Q. A novel drug delivery system: hyodeoxycholic acid-modified metformin liposomes for type 2 diabetes treatment. Molecules. 2023 Mar 8;28(6):2471. https://doi.org/10.3390/molecules28062471 PMid:36985444 PMCid:PMC10055618

50. Pandey S, Shamim A, Shaif M, Kushwaha P. Development and evaluation of Resveratrol-loaded liposomes in hydrogel-based wound dressing for diabetic foot ulcer. Naunyn-Schmiedeberg's Archives of Pharmacology. 2023 Aug;396(8):1811-25. https://doi.org/10.1007/s00210-023-02441-5 PMid:36862150

51. Zhang K, Chen J, Raza F, Zafar H, Xu Y, Li R, Ullah KH, Zhou S. Advancing diabetes treatment: novel formulation of polydatin long-circulating liposomes and their glucose-regulating impact on hyperlipidemia-induced type 2 diabetic mice. Materials Advances. 2024;5(16):6516-34. https://doi.org/10.1039/D4MA00020J

52. Abou-Taleb HA, Aldosari BN, Zaki RM, Afzal O, Tulbah AS, Shahataa MG, Abo El-Ela FI, Salem HF, Fouad AG. Formulation and therapeutic evaluation of isoxsuprine-loaded nanoparticles against diabetes-associated stroke. Pharmaceutics. 2023 Aug 30;15(9):2242. https://doi.org/10.3390/pharmaceutics15092242 PMid:37765211 PMCid:PMC10536800

53. Vasanth S, Mishra R, Sahoo S, Parveen S, Khan Z, Mumtaz, Ruqaiya, Pal R. Advancing Mitochondrial Health in Huntington Disease (HD): Small Molecule Therapies and Neurodegeneration. Current aging science. 2025.

54. Sasidharan J, Meenakshi RV, SureshKumar P. Green synthesis, Characterization and Evaluation of In-vitro Antioxidant & Anti-diabetic Activity of Nanoparticles from A Polyherbal Formulation-Mehani. J. Environ. Nanotechnol. 2018;7(3):51-9. https://doi.org/10.13074/jent.2018.09.183316

55. Khatri N, Vaja PN, Krishna MM, BM K, Narapusetty N, Gogoi P, Sharma RK, Jahnavi P. Formulation and Evaluation of Metformin-Loaded Nanoparticles for Enhanced Oral Bioavailability and Antidiabetic Activity. International Journal of Environmental Sciences. 2025;11(19s):2025.

56. Dixit PV, Mishra DK, Sharma S, Gautam RK. Nanocarriers and diabetes: new vistas and the way ahead. Current Pharmaceutical Biotechnology. 2023 Sep 1;24(11):1420-9. https://doi.org/10.2174/1389201024666221227140728 PMid:36578251

57. Abdel‐Moneim A, Ramadan H. Novel strategies to oral delivery of insulin: Current progress of nanocarriers for diabetes management. Drug Development Research. 2022 Apr;83(2):301-16. https://doi.org/10.1002/ddr.21903 PMid:34859477

58. Singh LS. Developing nanocarrier-based formulations of antidiabetic drugs derived from medicinal plants: A systemic review. Pharmacological Research-Natural Products. 2024 Mar 1;2:100004. https://doi.org/10.1016/j.prenap.2023.100004

59. Cassini A, Colzani E, Pini A, Mangen MJ, Plass D, McDonald SA, Maringhini G, van Lier A, Haagsma JA, Havelaar AH, Kramarz P. Impact of infectious diseases on population health using incidence-based disability-adjusted life years (DALYs): results from the Burden of Communicable Diseases in Europe study, European Union and European Economic Area countries, 2009 to 2013. Eurosurveillance. 2018 Apr 19;23(16):17-00454. https://doi.org/10.2807/1560-7917.ES.2018.23.16.17-00454 PMid:29692315 PMCid:PMC5915974

60. Haagsma JA, Graetz N, Bolliger I, Naghavi M, Higashi H, Mullany EC, Abera SF, Abraham JP, Adofo K, Alsharif U, Ameh EA. The global burden of injury: incidence, mortality, disability-adjusted life years and time trends from the Global Burden of Disease study 2013. Injury prevention. 2016 Feb;22(1):3-18.

61. Trautmann S, Rehm J, Wittchen HU. The economic costs of mental disorders: Do our societies react appropriately to the burden of mental disorders?. The EMBO Reports. 2016 Sep 1;17(9):1245-9. https://doi.org/10.15252/embr.201642951 PMid:27491723 PMCid:PMC5007565

62. Nurchis MC, Pascucci D, Sapienza M, Villani L, D'Ambrosio F, Castrini F, Specchia ML, Laurenti P, Damiani G. Impact of the burden of COVID-19 in Italy: results of disability-adjusted life years (DALYs) and productivity loss. International journal of environmental research and public health. 2020 Jun;17(12):4233. https://doi.org/10.3390/ijerph17124233 PMid:32545827 PMCid:PMC7345321

63. Kassebaum NJ, Arora M, Barber RM, Bhutta ZA, Brown J, Carter A, Casey DC, Charlson FJ, Coates MM, Coggeshall M, Cornaby L. Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. The Lancet. 2016 Oct 8;388(10053):1603-58.

64. Pal, Rahul & Koli, Manju & Shah, Tapaskumar & Dutta, Prottay & Ghosh, Binita & Patel, Neetu & Patel, Abhay & Singh, Akashdeep. (2025). Non-Ionic Surfactants (NIOs) in Niosome Drug Delivery: In-Depth Review on Clinical Trials, Patents in Tuberculosis (TB) and Oncology. Current Nanomedicine. 16. https://doi.org/10.2174/0124681873413153251014082026

65. Arias D, Saxena S, Verguet S. Quantifying the global burden of mental disorders and their economic value. EClinicalMedicine. 2022 Dec 1;54. https://doi.org/10.1016/j.eclinm.2022.101675 PMid:36193171 PMCid:PMC9526145

66. Chu DT, Nguyet NT, Dinh TC, Lien NV, Nguyen KH, Ngoc VT, Tao Y, Son LH, Le DH, Nga VB, Jurgoński A. An update on physical health and economic consequences of overweight and obesity. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2018 Nov 1;12(6):1095-100. https://doi.org/10.1016/j.dsx.2018.05.004 PMid:29799416

67. Alcaraz A, Bardach AE, Espinola N, Perelli L, Rodriguez Cairoli F, La Foucade A, de Mello Vianna CM, Guevara G, Gittens-Baynes KA, Johns P, Beharry V. Health and economic burden of disease of sugar-sweetened beverage consumption in four Latin American and Caribbean countries: a modelling study. BMJ open. 2023 Feb;13(2):e062809. https://doi.org/10.1136/bmjopen-2022-062809 PMid:36750287 PMCid:PMC9906178

68. Stevens B, Pezzullo L, Verdian L, Tomlinson J, George A, Bacal F. The economic burden of heart conditions in Brazil. Arquivos brasileiros de cardiologia. 2018;111:29-36. https://doi.org/10.5935/abc.20180104 PMid:30110042 PMCid:PMC6078379

69. Gupta U, Kosey S, Pal R. Advancements in nanotechnology-based targeted drug delivery systems for glioblastoma chemotherapy: A comprehensive review. Journal of Drug Delivery Science and Technology. 2025 Sep 1;111:107181. https://doi.org/10.1016/j.jddst.2025.107181

70. Diabetes GB, Fischer F, Moraga P, Ribeiro D, Violante FS, Schmidt MI, Sadeghi E, Kimokoti RW, Kivimäki M, Khafaie MA, Bijani A. Estimates, trends, and drivers of the global burden of type 2 diabetes attributable to PM2· 5 air pollution, 1990-2019: an analysis of data from the Global Burden of Disease Study 2019. The lancet/Planetary health. 2022;6(DKFZ-2022-02796):e586-600.

71. Burkart K, Causey K, Cohen AJ, Wozniak SS, Salvi DD, Abbafati C, Adekanmbi V, Adsuar JC, Ahmadi K, Alahdab F, Al-Aly Z. Estimates, trends, and drivers of the global burden of type 2 diabetes attributable to PM2· 5 air pollution, 1990-2019: an analysis of data from the Global Burden of Disease Study 2019. The Lancet Planetary Health. 2022 Jul 1;6(7):e586-600.

72. Pal, Rahul & Ghosh, Binita & Dutta, Prottay & Kumar, Amar & Sahoo, Subhashree & Mishra, Rakhi. (2026). Lipidic Nanocarriers (Liposomes): A Potential Targeting Strategy for Cosmeceutical Applications and Therapeutic Applications-An In-Depth Review. Current Nanomedicine. 16. https://doi.org/10.2174/0124681873411316251118051648

73. Xie J, Wang M, Long Z, Ning H, Li J, Cao Y, Liao Y, Liu G, Wang F, Pan A. Global burden of type 2 diabetes in adolescents and young adults, 1990-2019: systematic analysis of the Global Burden of Disease Study 2019. Bmj. 2022 Dec 7;379. https://doi.org/10.1136/bmj-2022-072385 PMid:36740855 PMCid:PMC9727920

74. Wang W, Hu M, Liu H, Zhang X, Li H, Zhou F, Liu YM, Lei F, Qin JJ, Zhao YC, Chen Z. Global Burden of Disease Study 2019 suggests that metabolic risk factors are the leading drivers of the burden of ischemic heart disease. Cell metabolism. 2021 Oct 5;33(10):1943-56. https://doi.org/10.1016/j.cmet.2021.08.005 PMid:34478633

75. Zhang Y, Lazzarini PA, McPhail SM, van Netten JJ, Armstrong DG, Pacella RE. Global disability burdens of diabetes-related lower-extremity complications in 1990 and 2016. Diabetes care. 2020 May 1;43(5):964-74. https://doi.org/10.2337/dc19-1614 PMid:32139380

76. Abdul Basith Khan M, Hashim MJ, King JK, Govender RD, Mustafa H, Al Kaabi J. Epidemiology of type 2 diabetes-global burden of disease and forecasted trends. Journal of epidemiology and global health. 2020 Mar;10(1):107-11.https://doi.org/10.2991/jegh.k.191028.001 PMid:32175717 PMCid:PMC7310804

77. Shukla K, Vasanth S, Mishra R, Sahoo S, Saxena G, Shah TM, et al. Nanoparticles (NPs) as a cutting-edge therapeutic strategy and their current status in tuberculosis (TB): a comprehensive review. Recent Adv Drug Deliv Formul. 2026;20:1-49. https://doi.org/10.2174/0126673878403646251209194351 PMid:41968556

78. Awad SF, A Toumi A, A Al-Mutawaa K, A Alyafei S, A Ijaz M, AH Khalifa S, B Kokku S, CM Mishra A, V Poovelil B, B Soussi M, G El-Nahas K. Type 2 diabetes epidemic and key risk factors in Qatar: a mathematical modeling analysis. BMJ Open Diabetes Research & Care. 2022 Apr;10(2):e002704. https://doi.org/10.1136/bmjdrc-2021-002704 PMid:35443971 PMCid:PMC9021773

79. Pal, Rahul & Mandal, Raj & Shah, Tapaskumar & Singh, Anjali & Sahoo, Subhashree. (2026). Gastro-Retentive Drug Delivery Systems (GRDDs) as a Promising Strategy for Disease Targeting: A Comprehensive Review. Drug Delivery Letters. 10.2174/0122103031410778251206145139.

80. Liang R, Long J, Zheng Q, Yuan G, Chen X, Xin Z, Lai F, Liu Y. Current landscape of type 1 diabetes mellitus-related interventional clinical trials registered on ClinicalTrials. gov: a cross-sectional study. Acta Diabetologica. 2021 Jun;58(6):723-33. https://doi.org/10.1007/s00592-020-01627-0 PMid:33543370

81. Singh JV, Bedi PM, Singh H, Sharma S. Xanthine oxidase inhibitors: patent landscape and clinical development (2015-2020). Expert Opinion on Therapeutic Patents. 2020 Oct 2;30(10):769-80. https://doi.org/10.1080/13543776.2020.1811233 PMid:32797760

82. Litvinova O, Klager E, Tzvetkov NT, Kimberger O, Kletecka-Pulker M, Willschke H, Atanasov AG. Digital pills with ingestible sensors: patent landscape analysis. Pharmaceuticals. 2022 Aug 19;15(8):1025. https://doi.org/10.3390/ph15081025 PMid:36015173 PMCid:PMC9415622

83. Ghosh, Binita & Sharma, Pratiksha & Goyal, Saloni & Chaturvedi, Varunesh & Reena, Km & Pal, Rahul. (2026). Next-Generation Nanocarriers-Based Nanoformulations for Polycystic Ovary Syndrome (PCOS): A Deep Insight into Clinical and Patents Perspectives. Drug Delivery Letters. 16. https://doi.org/10.2174/0122103031426128260310065402

84. Karachaliou F, Simatos G, Simatou A. The challenges in the development of diabetes prevention and care models in low-income settings. Frontiers in endocrinology. 2020 Aug 13;11:518. https://doi.org/10.3389/fendo.2020.00518 PMid:32903709 PMCid:PMC7438784

85. Avilés-Santa ML, Monroig-Rivera A, Soto-Soto A, Lindberg NM. Current state of diabetes mellitus prevalence, awareness, treatment, and control in Latin America: challenges and innovative solutions to improve health outcomes across the continent. Current diabetes reports. 2020 Nov;20(11):62. https://doi.org/10.1007/s11892-020-01341-9 PMid:33037442 PMCid:PMC7546937

86. Pati MK, Swaroop N, Kar A, Aggarwal P, Jayanna K, Van Damme W. A narrative review of gaps in the provision of integrated care for noncommunicable diseases in India. Public Health Reviews. 2020 May 13;41(1):8. https://doi.org/10.1186/s40985-020-00128-3 PMid:32435518 PMCid:PMC7222468

87. Godman B, Basu D, Pillay Y, Mwita JC, Rwegerera GM, Anand Paramadhas BD, Tiroyakgosi C, Okwen PM, Niba LL, Nonvignon J, Sefah I. Review of ongoing activities and challenges to improve the care of patients with type 2 diabetes across Africa and the implications for the future. Frontiers in pharmacology. 2020 Mar 20;11:108. https://doi.org/10.3389/fphar.2020.00108 PMid:32265688 PMCid:PMC7098994

88. Mohseni M, Ahmadi S, Azami-Aghdash S, Isfahani HM, Moosavi A, Fardid M, Etemadi M, Ghazanfari F. Challenges of routine diabetes care during COVID-19 era: a systematic search and narrative review. Primary care diabetes. 2021 Dec 1;15(6):918-22. https://doi.org/10.1016/j.pcd.2021.07.017 PMid:34393092 PMCid:PMC8326007

89. Flor LS, Wilson S, Bhatt P, Bryant M, Burnett A, Camarda JN, Chakravarthy V, Chandrashekhar C, Chaudhury N, Cimini C, Colombara DV. Community-based interventions for detection and management of diabetes and hypertension in underserved communities: a mixed-methods evaluation in Brazil, India, South Africa and the USA. BMJ Global Health. 2020 Jun;5(6):e001959. https://doi.org/10.1136/bmjgh-2019-001959 PMid:32503887 PMCid:PMC7279660

90. Nadeem MW, Goh HG, Hussain M, Liew SY, Andonovic I, Khan MA. Deep learning for diabetic retinopathy analysis: a review, research challenges, and future directions. Sensors. 2022 Sep 8;22(18):6780. https://doi.org/10.3390/s22186780 PMid:36146130 PMCid:PMC9505428